KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Gross Profit (2016 - 2025)

Historic Gross Profit for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $3.6 billion.

  • Regeneron Pharmaceuticals' Gross Profit rose 298.06% to $3.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $13.2 billion, marking a year-over-year increase of 66.64%. This contributed to the annual value of $13.2 billion for FY2025, which is 66.64% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Gross Profit of $3.6 billion as of Q4 2025, which was up 298.06% from $3.5 billion recorded in Q3 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Gross Profit peaked at $4.6 billion during Q2 2021, and registered a low of -$178.0 million during Q4 2022.
  • Its 5-year average for Gross Profit is $2.9 billion, with a median of $3.2 billion in 2023.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Gross Profit crashed by 10670.65% in 2022 and then surged by 195187.54% in 2023.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Gross Profit stood at $4.1 billion in 2021, then crashed by 104.3% to -$178.0 million in 2022, then skyrocketed by 1884.1% to $3.2 billion in 2023, then rose by 9.03% to $3.5 billion in 2024, then rose by 2.98% to $3.6 billion in 2025.
  • Its Gross Profit stands at $3.6 billion for Q4 2025, versus $3.5 billion for Q3 2025 and $3.4 billion for Q2 2025.